Authors
G Ralph Corey, Samantha Good, Hai Jiang, Greg Moeck, Matthew Wikler, Sinikka Green, Paul Manos, Richard Keech, Rajesh Singh, Barry Heller, Natalia Bubnova, William O'Riordan
Publication date
2015/1/15
Journal
Clinical Infectious Diseases
Volume
60
Issue
2
Pages
254-262
Publisher
Oxford University Press
Description
A single 1200-mg dose of oritavancin was noninferior to 7–10 days of vancomycin for treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by gram-positive pathogens. Oritavancin provides a single-dose alternative to multi-dose therapies for ABSSSI.
Scholar articles
GR Corey, S Good, H Jiang, G Moeck, M Wikler… - Clinical Infectious Diseases, 2015